The shares of the corona vaccine pioneer BioNTech are recovering somewhat from the price slide of the past trading days.
After they had recently slumped by more than a quarter due to a cut sales target by competitor Moderna and the prospect of an effective corona pill from Pfizer in main New York trading, BioNTech shares were in US trading on NASDAQ on Monday 11.98 percent high on a closing price of $ 242.60. The Mainz-based company will publish its quarterly figures these days.
Experts consider the latest setback to be exaggerated. “Even if a new entry in stocks of pure vaccine specialists is currently not in fashion: Panic sales are not either,” said the stock exchange letter author Hans Bernecker on Monday. So far, new drugs to reduce the course of the disease have not changed the fact that the need for vaccinations is still being propagated. The Bryan Garnier analyst Olga Smolentseva, who suspects that vaccination efforts will not be interrupted, sees it similarly. Vaccinations remain the most effective approach to curb the spread of the virus for the time being, according to the expert.
BioNTech after the price slide: shares in positive territory at the start of the week
The BioNTech share was able to recover somewhat on Monday morning from its sharp slide in the previous week. The share rose on the Tradegate trading platform by 5.6 percent to 201.30 euros.
On Friday, news that Pfizer had an effective anti-coronavirus pill put massive pressure on vaccine stocks. The pill from the pharmaceutical company is said to reduce the risk of hospitalization or death by 89 percent. The approval is now to be submitted.
Investors feared that vaccines against the coronavirus could now be much less in demand. The vaccination is likely to remain the most important component of the nationwide campaigns in the fight against Corona. Booster vaccinations in particular are likely to play an important role.
From around the seventh, eighth or ninth month, the antibody level drops after vaccination with the vaccine from BioNTech / Pfizer. Then there could be an infection with the coronavirus. “We also observe that when infected, the disease progression in vaccinated people is usually moderate and severe progression rarely occurs,” says BioNTech boss Ugur Sahin. “And we have study data that show that a booster restores vaccination protection. This also applies to the Delta variant”.
Today, there could be an outlook for further business when BioNTech presents the figures for the third quarter. In the long term, however, the focus is clearly on the further pipeline – in particular the oncology projects. From a technical chart point of view, the BioNTech share was able to defend the 200-day line recently. This continues to act as an important support. The shareholder clearly remains confident in the long term.